Doyne honeycomb retinal dystrophy – functional improvement following subthreshold nanopulse laser treatment: a case report
Open Access
- 10 January 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Medical Case Reports
- Vol. 13 (1), 5
- https://doi.org/10.1186/s13256-018-1935-1
Abstract
Based on phenotypic similarities between age-related macular degeneration and the autosomal disorder Doyne honeycomb retinal dystrophy, we report on a single nanolaser treatment of a patient with genotype Doyne honeycomb retinal dystrophy confirmation and evidence of disease progression over 12 months. The case study is the first report of short-term results of subthreshold nanolaser treatment in a patient with Doyne honeycomb retinal dystrophy. A 43-year-old Caucasian man with moderate loss of visual acuity in his left eye (20/40) and normal visual acuity in his right eye (20/20), with clinical Doyne honeycomb retinal dystrophy diagnosis and genetic confirmation of the common heterozygous mutation (EFEMP1) by genetic testing, underwent nanopulse subthreshold laser treatment in his left eye. A safety examination, carried out 7 days after treatment, and clinical follow-up, conducted 60 days following laser treatment, showed improvement of visual acuity from baseline by two letters and a subjective improvement of blurring. While no apparent morphological changes were found on fundoscopy, increased autofluorescence in the treated eye was observed on imaging. In addition, 2 months after nanopulse subthreshold laser treatment, rod-mediated and cone-mediated full-field electroretinography b-wave amplitudes showed an increase from baseline in both the treated eye (300%) and untreated eye (50%). At 2 months after nanopulse subthreshold laser treatment, multifocal electroretinograms showed improvement. Acuity and full-field electroretinography improvement persisted at 6-month follow-up. Sustained improvements in retinal function on electroretinography persisted in both eyes 6 months after treatment, suggesting an enhancement of phototransduction and retinoid recycling induced by nanopulse subthreshold laser treatment. The functional improvement observed in the untreated eye is hypothesized to arise from an increased expression and release of metalloproteinases that circulate systemically.Keywords
This publication has 18 references indexed in Scilit:
- Multimodal morphological and functional characterization of Malattia LeventineseAlbrecht von Graefes Archiv für Ophthalmologie, 2012
- A Comparative Analysis of the Fibulin Protein FamilyJournal of Biological Chemistry, 2007
- Optical Coherent Tomography Features of Malattia LeventineseAmerican Journal of Ophthalmology, 2006
- Tomographie à Cohérence Optique dans la Malattia LeventineseKlinische Monatsblätter für Augenheilkunde, 2005
- Tissue Inhibitor of Metalloproteinases-3 (TIMP-3) Is a Binding Partner of Epithelial Growth Factor-containing Fibulin-like Extracellular Matrix Protein 1 (EFEMP1)Published by Elsevier BV ,2004
- Analysis of the EFEMP1 gene in individuals and families with early onset drusenEye, 2004
- Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degenerationProceedings of the National Academy of Sciences of the United States of America, 2002
- Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4Matrix Biology, 1999
- A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophyNature Genetics, 1999
- The gene responsible for autosomal dominant Doyne's honeycomb retinal dystrophy (DHRD) maps to chromosome 2p16 [published erratum appears in Hum Mol Genet 1996 Sep;5(9):1390]Human Molecular Genetics, 1996